FDA-approved tirzepatide (Mounjaro and Zepbound) is supplied as a clear, colorless to slightly yellow solution in single-dose pens
The number of days since the patient began psychiatric treatment was negatively correlated with the frequency of experiencing poor appetite ( r = 0.093, p = 0.018), but not with insomnia (r = 0.071, p = 0.073), end-of-dose crash ( r = 0.004, p = 0.923), or return of symptoms ( r = 0.009, p = 0.823)
4,172 Adverse side effects from rTMS are rare, but can include dizziness and mild neurological, psychological, or cognitive changes that may be temporary or persistent
16 weeks 16 syringes 1 syringe per weekly injection 26 weeks 26 syringes 1 syringe per weekly injection 32 weeks 32 syringes 1 syringe per weekly injection 68 weeks 68 syringes 1 box of 100 covers a long cycle Bacteriostatic Water (10 mL bottles) Each 5 mg vial uses 2.0 mL BAC water